Comparison of Cryoballoon Ablation Methods in Pulmonary Vein Isolation

Area of Science:

• Electrophysiology
• Cardiovascular Medicine
• Medical Devices

Background:

• Cryoballoon ablation is a key therapy for atrial fibrillation (AF).
• Pulmonary vein isolation (PVI) is achieved via a single-shot technique.
• Existing cryoballoon systems, Medtronic Arctic Front and Boston Scientific POLARx, have differing characteristics, necessitating direct comparison.

Purpose of the Study:

• To compare the biophysical parameters and mid-term outcomes of the POLARx and Arctic Front cryoballoon systems.
• To evaluate differences in cooling kinetics and procedural efficiency.
• To assess the safety and efficacy of both systems in patients with AF.

Main Methods:

• Retrospective analysis of 200 patients undergoing cryoballoon ablation for AF.
• Patients were grouped by ablation system: POLARx (n=107) and Arctic Front (n=93).
• Key parameters assessed included nadir temperatures, time to -40°C, procedure duration, dose area product, complications, and AF recurrence.

Main Results:

• POLARx achieved significantly lower nadir temperatures and faster time to -40°C in all pulmonary veins compared to Arctic Front (p<0.001).
• Despite superior cooling, POLARx procedures were longer (64.7 vs. 51.6 min, p<0.001).
• Mid-term AF recurrence (11.8 months) and complication rates (e.g., phrenic nerve palsy) were similar between systems.

Conclusions:

• The POLARx system exhibits superior cooling kinetics and biophysical performance.
• Both cryoballoon systems demonstrate comparable mid-term efficacy and safety for PVI in AF patients.
• Further research may explore long-term outcomes and specific patient selection criteria for each system.